Here are Thursday's biggest analyst calls: Nvidia, Apple, Broadcom, Snowflake, Deere, Tesla, Amazon & more

Wall Street’s biggest calls are mixed, with Evercore ISI flagging Apple’s App Store weakness: August App Store revenues fell -1% y/y (sixth straight month of deceleration) and gaming revenue was down ~10% y/y. Offsetting the caution, Bank of America reiterated Nvidia as Buy at ~16x CY27 P/E, and Snowflake’s F2Q27 showed accelerating product revenue growth to 37% y/y (from 34% in F1Q27). Overall, the setup is skewed slightly cautious due to Apple’s App Store trend, despite multiple upside-leaning rating initiations/reiterates.

Analysis

This read-through is less about single-name alpha than a factor rotation: analysts are crowding into companies with visible operating leverage to secular capex, while becoming less forgiving of consumer monetization and pre-profit biotech. That favors a basket of AI infrastructure and adjacent picks—AVGO, NVDA, AMZN, SNOW—where even modest demand confirmation can drive multiple expansion because revisions are still early and positioning is not yet saturated. The second-order effect is important: if hyperscaler spend remains intact, the supply chain winners broaden from chips into networking, software attach, and power-management names, which argues for staying long the picks-and-shovels rather than chasing the most crowded front-end beneficiaries.

Nuclear is emerging as the cleaner medium-term trade than conventional energy because the bull case is anchored in procurement, regulation, and long-duration infrastructure, not spot commodity beta. CCJ and BWXT have different earnings sensitivities but the same end-market tailwind: a multi-year shortage of qualified supply and a rising willingness of data-center buyers to pay for baseload certainty. The risk is timing—equity performance can outrun the underlying buildout by 6-12 months—so the best entry is on any pullback tied to uranium spot consolidation or a delay in utility contracting, not after another momentum chase.

On the other side, AAPL and MRNA look vulnerable to narrative fatigue. For AAPL, the issue is not absolute demand but the durability of services growth versus a slowing gaming mix; that matters because services is the margin lever that supports the multiple. For MRNA, the market may be paying for an oncology platform before the cash-flow evidence exists; unless the next data readouts translate into a clearer commercial path, the stock is exposed to a sharp de-rating over the next 1-3 months.

Key Decisions for Investors

• Go long AVGO/NVDA on any 3-5% pullback over the next 2 weeks; catalyst is the next AI capex commentary cycle, with upside if revenue/opex revisions keep ratcheting higher and downside if hyperscaler demand guides flatten.
• Initiate a 3-6 month long CCJ + BWXT basket on weakness; thesis is structural scarcity in nuclear supply and service, with risk if uranium spot rolls over or utility contracting slows materially.
• Short MRNA on a 1-3 month horizon or buy put spreads into strength; the risk/reward is attractive if the market is pricing commercialization too early, and the thesis is falsified by a new data set that clearly broadens the revenue runway.
• Use AAPL as a relative-value short against AMZN or NVDA rather than as an outright short; the pair expresses secular capex growth versus slower services monetization, and should work unless App Store growth re-accelerates over the next two quarters.
• Add DE/CNH on a 6-12 month horizon only on pullbacks; the trade works if farm-economics normalization continues, but is invalidated by another down-leg in crop income or equipment order cancellations.